Nuvation Bio Inc (NUVB)
NYSE:NUVB
Want to see NUVB full AI Analyst Report?
Total Valuation
Nuvation Bio has a market cap or net worth of $1.57B. The enterprise value is $1.55B.
Market Cap$1.57B
Enterprise Value$1.55B
Share Statistics
Nuvation Bio has 348,201,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding348,201,970
Owned by Insiders24.80%
Owned by Institutions20.37%
Financial Efficiency
Nuvation Bio’s return on equity (ROE) is -0.67 and return on invested capital (ROIC) is -40.96%.
Return on Equity (ROE)-0.67
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-40.96%
Return on Capital Employed (ROCE)-0.42
Revenue Per Employee230.41K
Profits Per Employee-749.55K
Employee Count273
Asset Turnover0.11
Inventory Turnover0.74
Valuation Ratios
The current PE Ratio of Nuvation Bio is 69.0. Nuvation Bio’s PEG ratio is 0.21.
PE Ratio69.0
PS Ratio48.65
PB Ratio10.01
Price to Fair Value10.01
Price to FCF-17.61
Price to Operating Cash Flow-13.23
PEG Ratio0.21
Income Statement
In the last 12 months, Nuvation Bio had revenue of 62.90M and earned -204.63M in profits. Earnings per share was -0.60.
Revenue62.90M
Gross Profit54.46M
Operating Income-213.06M
Pretax Income-204.63M
Net Income-204.63M
EBITDA-190.94M
Earnings Per Share (EPS)-0.60
Cash Flow
In the last 12 months, operating cash flow was -125.73M and capital expenditures -330.00K, giving a free cash flow of -126.06M billion.
Operating Cash Flow-125.73M
Free Cash Flow-126.06M
Free Cash Flow per Share-0.36
Dividends & Yields
Nuvation Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change112.89%
50-Day Moving Average4.58
200-Day Moving Average5.11
Relative Strength Index (RSI)53.79
Average Volume (3m)4.13M
Important Dates
Nuvation Bio upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 4, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Nuvation Bio as a current ratio of 6.95, with Debt / Equity ratio of 3.08%
Current Ratio6.95
Quick Ratio6.81
Debt to Market Cap<0.01
Net Debt to EBITDA0.81
Interest Coverage Ratio-15.57
Taxes
In the past 12 months, Nuvation Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nuvation Bio EV to EBITDA ratio is -15.22, with an EV/FCF ratio of -16.72.
EV to Sales46.20
EV to EBITDA-15.22
EV to Free Cash Flow-16.72
EV to Operating Cash Flow-16.76
Balance Sheet
Nuvation Bio has $533.73M in cash and marketable securities with $9.83M in debt, giving a net cash position of $523.90M billion.
Cash & Marketable Securities$533.73M
Total Debt$9.83M
Net Cash$523.90M
Net Cash Per Share$1.50
Tangible Book Value Per Share$0.86
Margins
Gross margin is 91.64%, with operating margin of -338.72%, and net profit margin of -325.31%.
Gross Margin91.64%
Operating Margin-338.72%
Pretax Margin-325.31%
Net Profit Margin-325.31%
EBITDA Margin-303.56%
EBIT Margin-303.56%
Analyst Forecast
The average price target for Nuvation Bio is $13.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.17
Price Target Upside159.19% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast1205.52%
EPS Growth Forecast81.79%